Ovid Therapeutics (OVID) to Announce Quarterly Earnings on Wednesday

Ovid Therapeutics (NASDAQ:OVID) is projected to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $0.0210 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Tuesday, May 12th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). Ovid Therapeutics had a negative net margin of 240.11% and a negative return on equity of 22.51%. On average, analysts expect Ovid Therapeutics to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ovid Therapeutics Stock Up 9.0%

Shares of Ovid Therapeutics stock opened at $2.54 on Wednesday. Ovid Therapeutics has a 52-week low of $0.48 and a 52-week high of $3.11. The company has a 50 day moving average of $2.45 and a 200 day moving average of $2.25. The company has a quick ratio of 10.17, a current ratio of 10.17 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $474.07 million, a P/E ratio of -8.76 and a beta of 0.21.

Wall Street Analysts Forecast Growth

OVID has been the subject of a number of analyst reports. Oppenheimer boosted their target price on shares of Ovid Therapeutics from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Friday, July 17th. HC Wainwright lifted their price target on Ovid Therapeutics from $2.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Wedbush reaffirmed an “outperform” rating and set a $7.00 price target on shares of Ovid Therapeutics in a report on Wednesday, April 15th. Finally, Roth Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Ovid Therapeutics in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Ovid Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $5.38.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE lifted its position in Ovid Therapeutics by 49.7% in the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after acquiring an additional 18,841 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Ovid Therapeutics by 12.8% during the first quarter. Acadian Asset Management LLC now owns 2,088,046 shares of the company’s stock worth $650,000 after purchasing an additional 237,445 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Ovid Therapeutics during the second quarter worth about $54,000. Jane Street Group LLC purchased a new stake in shares of Ovid Therapeutics in the 2nd quarter valued at about $47,000. Finally, Rosalind Advisors Inc. acquired a new stake in shares of Ovid Therapeutics in the 2nd quarter valued at about $165,000. 72.24% of the stock is owned by hedge funds and other institutional investors.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.